CYAD Celyad SA

8.43
-0.06  -1%
Previous Close 8.49
Open 8.35
Price To Book 2.35
Market Cap 117,533,960
Shares 13,942,344
Volume 8,403
Short Ratio
Av. Daily Volume 12,092
Stock charts supplied by TradingView

NewsSee all news

  1. Celyad Announces First Quarter 2020 Financial Results and Recent Business Highlights

    MONT-SAINT-GUIBERT, Belgium, May 07, 2020 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  2. Celyad Appoints Seasoned Industry Executives to Board of Directors

    MONT-SAINT-GUIBERT, Belgium, May 06, 2020 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  3. Celyad to Present Update from CYAD-101 for Advanced Colorectal Cancer and Next-Generation shRNA Platform at 2020 ASCO Virtual Scientific Program

    Two accepted abstracts will be presented virtually in a prerecorded poster presentation MONT-SAINT-GUIBERT, Belgium, April 30, 2020 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a

  4. Celyad to Host Remote 2020 Ordinary General Meeting

    MONT-SAINT-GUIBERT, Belgium, April 22, 2020 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  5. Celyad Reports Full Year 2019 Financial Results and Provides Business Update

    First patient successfully dosed in expansion cohort of autologous CYAD-01 THINK trial  for  patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)CYCLE-1 trial of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data did not meet primary endpoint
C-Cure - Chart 1 trial
Chronic Heart Failure secondary to ischemic cardiomyopathy
Phase 1 expansion data due 2H 2020.
CYAD-01 - THINK
Various cancers - solid and hematologic cancers
Phase 1 further data due at ASCO May 29, 2020.
CYAD-101 - alloSHRINK (ASCO)
Colorectal cancer
Phase 1 data presented at SITC November 8, 2019.
CYAD-01 and FOLFOX - SHRINK
Colorectal cancer
Phase 1 dose escalation data due 2H 2020.
CYAD-01 and chemotherapy (DEPLETHINK)
AML or myelodysplastic syndrome (MDS)
Phase 1 data due 2H 2020.
CYAD-02 CYCLE-1
Relapsed/refractory Acute myeloid leukemia (AML) and Myelodysplastic Syndrome (MDS)

Latest News

  1. Celyad Announces First Quarter 2020 Financial Results and Recent Business Highlights

    MONT-SAINT-GUIBERT, Belgium, May 07, 2020 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  2. Celyad Appoints Seasoned Industry Executives to Board of Directors

    MONT-SAINT-GUIBERT, Belgium, May 06, 2020 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  3. Celyad to Present Update from CYAD-101 for Advanced Colorectal Cancer and Next-Generation shRNA Platform at 2020 ASCO Virtual Scientific Program

    Two accepted abstracts will be presented virtually in a prerecorded poster presentation MONT-SAINT-GUIBERT, Belgium, April 30, 2020 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a

  4. Celyad to Host Remote 2020 Ordinary General Meeting

    MONT-SAINT-GUIBERT, Belgium, April 22, 2020 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  5. Celyad Reports Full Year 2019 Financial Results and Provides Business Update

    First patient successfully dosed in expansion cohort of autologous CYAD-01 THINK trial  for  patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)CYCLE-1 trial of

  6. Celyad to Announce Full Year 2019 Financial Results and Host Conference Call

    MONT-SAINT-GUIBERT, Belgium, March 12, 2020 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  7. Celyad Appoints Stephen Rubino as Chief Business Officer

    MONT-SAINT-GUIBERT, Belgium, March 02, 2020 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  8. Celyad Announces February and March 2020 Conference Schedule

    MONT-SAINT-GUIBERT, Belgium, Feb. 17, 2020 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  9. Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

    Preliminary data from the Phase 1 CYCLE-1 trial are expected during second half 2020 MONT-SAINT-GUIBERT, Belgium, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage

  10. Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

    Future development of relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) program to be underpinned by proprietary OptimAb manufacturing processEnrollment of DEPLETHINK trial

  11. Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

    MONT-SAINT-GUIBERT, Belgium, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  12. Celyad Announces Board of Directors Evolution with New Appointment

    Dr. Christian Homsy steps down from the Celyad Board of Directors as current CEO Filippo Petti is nominated into the role MONT-SAINT-GUIBERT, Belgium, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and

  13. Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

    Funding will support the advancement of the Company's autologous and allogeneic CAR-T cell therapy programs  MONT-SAINT-GUIBERT, Belgium, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris,

  14. Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

    MONT-SAINT-GUIBERT, Belgium, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  15. Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

    Results from ongoing, dose-escalation alloSHRINK Phase 1 trial demonstrate absence of graft-versus-host disease for first-in-class, non-gene edited allogeneic CAR-T candidate, CYAD-101, when administered concurrently

  16. Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

    Management to host webcast on Saturday, Nov. 9, at 12:35 p.m. ET/ 6:35 p.m. CET MONT-SAINT-GUIBERT, Belgium, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage

  17. Celyad Announces October and November 2019 Investor Conference Schedule

    MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  18. Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

    Poster presentations to highlight allogeneic and autologous NKG2D-based CAR-T therapies for the treatment of advanced metastatic colorectal (mCRC) cancers MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) --

  19. Celyad Announces Closing of $20 Million Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  20. Horizon Discovery Group plc: Results for the Six Months Ended 30 June 2019

    RNS Horizon Discovery Group plcResults for the Six Months Ended 30 June 2019 Cambridge, UK, 16 September 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global

  21. Celyad Announces Pricing of $20.0 Million Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  22. Celyad Announces Launch of Proposed Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies,

  23. Be The Match BioTherapies® and Celyad Announce Collaboration to Advance Development of Allogeneic CAR-T Therapies

    Alliance will support the clinical progression of Celyad's non-gene edited allogeneic CAR-T candidates Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell

  24. Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

    MONT-SAINT-GUIBERT, Belgium, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  25. Celyad to Participate in Upcoming September 2019 Conferences

    MONT-SAINT-GUIBERT, Belgium, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  26. Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights

    MONT-SAINT-GUIBERT, Belgium, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today